Bluegnome's 24sure microarray technology has been used to screen polar bodies for all 24 chromosomes and select a euploid (normal chromosome content) egg that resulted in a successful pregnancy.
Prof Simon Fishel, managing director of Care Fertility Group, said: 'Chromosomal abnormality plays a major part in the failure to establish a pregnancy.
'Full chromosome analysis may double the chance of success in couples who have a poor chance of conceiving or a history of failed treatments and miscarriage; and maximise the chance of pregnancy in all couples.
'Up to half of the eggs in younger women and up to 75 per cent in women over 39 are chromosomally abnormal.
'The 24sure technology can be used to screen eggs/or embryos in an IVF cycle, evaluate all the chromosomes and select the most chromosomally normal embryos.'
The successful birth followed 13 previous failed IVF cycles and the mother was 41 years of age at the time of treatment.
As part of a consented study, eight eggs were tested using 24sure and only two were found to be chromosomally normal - one of these led to the birth.
Dr Nick Haan, chief executive officer at Bluegnome, said: '24sure technology has been developed specifically to analyse single cells for chromosomal aneuploidy and we believe that this technology may have a major future in pre-implantation genetic screening.
'However, it is important to emphasise that clinical data is still limited and carefully designed trials are required to properly assess efficacy of the technique.'
